Healthcare company Baxter International (NYSE:BAX) reported in Q1 CY2026, with sales up 2.9% year on year to $2.70 billion.

Baxter (BAX) stock jumps as the company exceeds Street forecasts with its Q1 2026 financials thanks to international sales.

Baxter President and CEO Andrew Hider's total compensation for 2025 makes him one of the highest paid CEOs in medtech.

Baxter stock gains attention after strong sales performance. Explore key drivers, healthcare trends, and factors shaping ...

Healthcare company Baxter International (NYSE:BAX) will be announcing earnings results this Thursday before market hours.

Establishes Vantive as a leading standalone kidney care business backed by Carlyle’s global investment team and resources Sale follows robust process focused on maximizing stockholder value Provides ...

Baxter’s latest quarterly performance highlights steady healthcare demand, evolving strategy, and its positioning within the ...

Baxter International posted a first-quarter loss on higher expenses and one-off items but the health-care conglomerate's sales growth exceeded Wall Street expectations and it backed 2026 growth ...

Following a number of changes at Baxter International, aimed at strengthening the company’s long-term outlook, the medical device and equipment company beat Wall Street estimates in the third quarter ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Baxter International is considering selling its kidney ...

April 30 (Reuters) - Baxter on Thursday beat Wall Street estimates for first-quarter profit and revenue, helped by robust sales in its medical products and therapies unit. Shares of the ...

The Deerfield, Illinois-based company reported sales of $3.85 billion, in line with consensus. Baxter’s worldwide sales include continuing sales of $2.69 billion and discontinued operations (kidney ...